County of San Luis Obispo Public Health Department Lidocaine (Xylocaine®)

Division: Emergency Medical Services Agency Effective Date: 04/15/2017

## LIDOCAINE (Xylocaine®)

Classification: Antidysrhythmic agent

**Action**: Suppresses ventricular ectopy by stabilizing the myocardial cell membrane.

Indications:

- 1. Cardiac arrest with ventricular fibrillation or pulseless ventricular tachycardia
- 2. Post conversion or defibrillation of ventricular rhythms with base contact.
- 3. Ventricular tachycardia with pulse present
- 4. Symptomatic/malignant ventricular ectopy

#### **Contraindications:**

- 1. 2° degree type II heart block
- 2. 3° degree heart block
- 3. Junctional bradycardia
- 4. Ventricular ectopy associated with bradycardia
- 5. Idioventricular rhythm
- 6. Known allergy to Lidocaine or sensitivity to other anesthetics (report to base).

### Adverse Effects: Cardiovascular

CardiovascularNeurologicalBradycardiaDizzinessHypotensionDrowsinessArrestParesthesiaBlurred visionRestlessnessSlurred speechRespiratoryDisorientation

Dyspnea Seizures

Depression Lightheadedness

Apnea Tinnitus

Muscle twitching

Gastrointestinal Nausea/vomiting

#### Administration: A

#### **ADULT DOSE**

- 1. **V-Fib/pulseless V-Tach:** 1.5 mg/kg IVP/IO, repeat every 3-5 minutes, not to exceed 3 mg/kg
- 2. **V-Tach with a pulse:** 1.5 mg/kg IVP, may repeat with 0.75 mg/kg IVP every 5-10 minutes, not to exceed 3 mg/kg

#### **PEDIATRIC DOSE**

1. **V-Fib/pulseless V-Tach:** 1 mg/kg IVP/IO. May repeat every 5 minutes, not to exceed 3 mg/kg

# LIDOCAINE (Xylocaine®)—continued

2. **V-Tach with a pulse:** 1 mg/kg IVP/IO, may repeat with 0.5 mg/kg IVP/IO every 5-10 minutes, not to exceed 3 mg/kg

Onset: 30 - 90 seconds

**Duration**: 10 - 20 minutes

## Notes:

- In cases of premature ventricular contractions, assess need and treat underlying cause. Needs include: chest pain, syncope, R on T situations, multifocal and paired PVCs, bigeminy and trigeminy, and PVCs at 6-12 per minute. See appropriate protocols as needed.
- Lidocaine is to be administered no faster than 50mg/min, except in patients in cardiac arrest.